231 related articles for article (PubMed ID: 35849803)
1. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease.
Papazoglou A; Huang M; Bulik M; Lafyatis A; Tabib T; Morse C; Sembrat J; Rojas M; Valenzi E; Lafyatis R
Arthritis Rheumatol; 2022 Dec; 74(12):2003-2014. PubMed ID: 35849803
[TBL] [Abstract][Full Text] [Related]
2. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
Front Immunol; 2021; 12():595811. PubMed ID: 33859634
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
4. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.
Mendoza FA; Piera-Velazquez S; Farber JL; Feghali-Bostwick C; Jiménez SA
Arthritis Rheumatol; 2016 Jan; 68(1):210-7. PubMed ID: 26360820
[TBL] [Abstract][Full Text] [Related]
7. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
Mathai SK; Gulati M; Peng X; Russell TR; Shaw AC; Rubinowitz AN; Murray LA; Siner JM; Antin-Ozerkis DE; Montgomery RR; Reilkoff RA; Bucala RJ; Herzog EL
Lab Invest; 2010 Jun; 90(6):812-23. PubMed ID: 20404807
[TBL] [Abstract][Full Text] [Related]
8. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
9. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
[TBL] [Abstract][Full Text] [Related]
10. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.
Christmann RB; Sampaio-Barros P; Stifano G; Borges CL; de Carvalho CR; Kairalla R; Parra ER; Spira A; Simms R; Capellozzi VL; Lafyatis R
Arthritis Rheumatol; 2014 Mar; 66(3):714-25. PubMed ID: 24574232
[TBL] [Abstract][Full Text] [Related]
11. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
[TBL] [Abstract][Full Text] [Related]
12. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.
Lindahl GE; Stock CJ; Shi-Wen X; Leoni P; Sestini P; Howat SL; Bou-Gharios G; Nicholson AG; Denton CP; Grutters JC; Maher TM; Wells AU; Abraham DJ; Renzoni EA
Respir Res; 2013 Aug; 14(1):80. PubMed ID: 23915349
[TBL] [Abstract][Full Text] [Related]
13. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.
Gao X; Jia G; Guttman A; DePianto DJ; Morshead KB; Sun KH; Ramamoorthi N; Vander Heiden JA; Modrusan Z; Wolters PJ; Jahreis A; Arron JR; Khanna D; Ramalingam TR
Cell Rep Med; 2020 Nov; 1(8):100140. PubMed ID: 33294861
[TBL] [Abstract][Full Text] [Related]
15. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.
Akter T; Silver RM; Bogatkevich GS
Curr Rheumatol Rep; 2014 Apr; 16(4):411. PubMed ID: 24523015
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.
Liu S; Chung MP; Ley B; French S; Elicker BM; Fiorentino DF; Chung LS; Boin F; Wolters PJ
Thorax; 2021 Dec; 76(12):1186-1192. PubMed ID: 34272332
[TBL] [Abstract][Full Text] [Related]
18. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation.
Stock CJW; Michaeloudes C; Leoni P; Durham AL; Mumby S; Wells AU; Chung KF; Adcock IM; Renzoni EA; Lindahl GE
Biomed Res Int; 2019; 2019():1484736. PubMed ID: 31119153
[TBL] [Abstract][Full Text] [Related]
20. miR-155 in the progression of lung fibrosis in systemic sclerosis.
Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
